^
Association details:
| Biomarker: | EGFR mutation + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + gumarontinib (SCC244) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
305MO - SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
Published date:
11/28/2022
Excerpt:
Overall, ORR was 60% [95% CI:40.6, 77.3], mDOR was 5.8 months [95% CI:3.9, 12.7 ], mPFS was 6.9 months [95% CI: 3.9, 8.9] and mOS was 16.9 months [95% CI:11.1, NE ]….SCC244 plus Osimertinib demonstrated clinical activity in EGFR-mutant NSCLC pts with METamp and resistant to EGFR TKI.
Trial ID:
